New Releases from NCBI BookshelfPembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.​Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.

Post Content

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top